Yong
Luo
a,
Yongxia
Zhu
a,
Kai
Ran
a,
Zhihao
Liu
a,
Ningyu
Wang
a,
Qiang
Feng
ac,
Jun
Zeng
a,
Lidan
Zhang
b,
Bing
He
ac,
Tinghong
Ye
a,
Shirui
Zhu
d,
Xiaolong
Qiu
e and
Luoting
Yu
*a
aSichuan University, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China. E-mail: yuluot@scu.edu.cn; Fax: +86 28 8516 4060; Tel: +86 28 8516 4063
bDepartment of Pharmaceutical and Bioengineering, School of Chemical Engineering, Sichuan University, Chengdu, Sichuan 610065, China
cCollege of Chemistry and Life Science, Chengdu Normal University, Chengdu 611130, China
dDepartment of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan University of Traditional Chinese Medicine, Zhengzhou, 450004, China
eWisdom Pharmaceutical Co. Ltd, Haimen, 226123, China
First published on 15th June 2015
Correction for 'Synthesis and biological evaluation of N-(4-phenylthiazol-2-yl)cinnamamide derivatives as novel potential anti-tumor agents' by Yong Luo et al., Med. Chem. Commun., 2015, 6, 1036.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2015 |